Clinuvel Pharmaceuticals Limited (CLVLF)
USD 7.45
(2.05%)
USD 7.45
(2.05%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 48 Million AUD | -1.57% |
| 2023 | 48.77 Million AUD | 33.27% |
| 2022 | 36.59 Million AUD | 33.9% |
| 2021 | 27.33 Million AUD | 107.65% |
| 2020 | 13.16 Million AUD | -27.42% |
| 2019 | 18.13 Million AUD | 49.3% |
| 2018 | 12.14 Million AUD | 81.29% |
| 2017 | 6.7 Million AUD | 260.14% |
| 2016 | -4.18 Million AUD | 62.84% |
| 2015 | -11.25 Million AUD | -77.87% |
| 2014 | -6.33 Million AUD | 23.55% |
| 2013 | -8.28 Million AUD | 19.65% |
| 2012 | -10.3 Million AUD | 19.05% |
| 2011 | -12.73 Million AUD | 22.27% |
| 2010 | -16.37 Million AUD | 9.97% |
| 2009 | -18.19 Million AUD | 3.49% |
| 2008 | -18.84 Million AUD | -69.0% |
| 2007 | -11.15 Million AUD | -15.3% |
| 2006 | -9.67 Million AUD | 21.54% |
| 2005 | -12.32 Million AUD | -41.15% |
| 2004 | -8.73 Million AUD | -78.0% |
| 2003 | -4.9 Million AUD | -18.34% |
| 2002 | -4.14 Million AUD | -77.15% |
| 2001 | -2.34 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | 32.21 Million AUD | 0.0% |
| 2024 FY | 55.13 Million AUD | 13.04% |
| 2024 Q1 | 6.94 Million AUD | -75.12% |
| 2024 Q2 | 11.33 Million AUD | 63.09% |
| 2023 Q2 | 12.97 Million AUD | 82.05% |
| 2023 FY | 48.77 Million AUD | 33.27% |
| 2023 Q1 | 7.12 Million AUD | -71.05% |
| 2023 Q3 | 14.93 Million AUD | 15.06% |
| 2023 Q4 | 27.93 Million AUD | 87.03% |
| 2022 Q1 | 4.75 Million AUD | -76.83% |
| 2022 FY | 36.59 Million AUD | 33.9% |
| 2022 Q4 | 24.62 Million AUD | 89.14% |
| 2022 Q3 | 13.02 Million AUD | 54.5% |
| 2022 Q2 | 8.42 Million AUD | 77.32% |
| 2021 Q2 | 6.2 Million AUD | 80.04% |
| 2021 Q4 | 20.51 Million AUD | 89.26% |
| 2021 Q3 | 10.83 Million AUD | 74.7% |
| 2021 Q1 | 3.44 Million AUD | -67.68% |
| 2021 FY | 27.33 Million AUD | 107.65% |
| 2020 Q4 | 10.65 Million AUD | 86.07% |
| 2020 FY | 13.16 Million AUD | -27.42% |
| 2020 Q1 | 396.24 Thousand AUD | -97.04% |
| 2020 Q2 | 1.9 Million AUD | 381.64% |
| 2020 Q3 | 5.72 Million AUD | 200.19% |
| 2019 Q2 | 1.64 Million AUD | -0.0% |
| 2019 Q3 | 6.69 Million AUD | 306.03% |
| 2019 FY | 18.13 Million AUD | 49.3% |
| 2019 Q1 | 1.64 Million AUD | -70.11% |
| 2019 Q4 | 13.39 Million AUD | 100.0% |
| 2018 Q3 | 5.51 Million AUD | 837.11% |
| 2018 Q4 | 5.51 Million AUD | 0.0% |
| 2018 Q2 | 588.87 Thousand AUD | -0.0% |
| 2018 FY | 12.14 Million AUD | 81.29% |
| 2018 Q1 | 588.87 Thousand AUD | -72.66% |
| 2017 Q2 | 1.24 Million AUD | 0.0% |
| 2017 Q1 | 1.24 Million AUD | 2650.55% |
| 2017 Q4 | 2.15 Million AUD | 0.0% |
| 2017 FY | 6.7 Million AUD | 260.14% |
| 2017 Q3 | 2.15 Million AUD | 72.95% |
| 2016 Q1 | -1.72 Million AUD | -8.8% |
| 2016 FY | -4.18 Million AUD | 62.84% |
| 2016 Q4 | -48.83 Thousand AUD | 0.0% |
| 2016 Q3 | -48.83 Thousand AUD | 97.17% |
| 2016 Q2 | -1.72 Million AUD | 0.0% |
| 2015 Q2 | -3.82 Million AUD | 0.0% |
| 2015 Q3 | -1.58 Million AUD | 58.55% |
| 2015 FY | -11.25 Million AUD | -77.87% |
| 2015 Q4 | -1.58 Million AUD | 0.0% |
| 2015 Q1 | -3.82 Million AUD | -218.44% |
| 2014 FY | -6.33 Million AUD | 23.55% |
| 2014 Q4 | -1.2 Million AUD | 0.0% |
| 2014 Q1 | -1.71 Million AUD | -25.25% |
| 2014 Q2 | -1.71 Million AUD | 0.0% |
| 2014 Q3 | -1.2 Million AUD | 29.84% |
| 2013 FY | -8.28 Million AUD | 19.65% |
| 2013 Q3 | -1.36 Million AUD | 0.0% |
| 2013 Q4 | -1.36 Million AUD | 0.0% |
| 2012 FY | -10.3 Million AUD | 19.05% |
| 2011 FY | -12.73 Million AUD | 22.27% |
| 2010 FY | -16.37 Million AUD | 9.97% |
| 2009 FY | -18.19 Million AUD | 3.49% |
| 2008 FY | -18.84 Million AUD | -69.0% |
| 2007 FY | -11.15 Million AUD | -15.3% |
| 2006 FY | -9.67 Million AUD | 21.54% |
| 2005 FY | -12.32 Million AUD | -41.15% |
| 2004 FY | -8.73 Million AUD | -78.0% |
| 2003 FY | -4.9 Million AUD | -18.34% |
| 2002 FY | -4.14 Million AUD | -77.15% |
| 2001 FY | -2.34 Million AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | 3922.121% |
| Skye Bioscience, Inc. | -13.67 Million USD | 451.13% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 41.35% |
| Nascent Biotech, Inc. | -2.22 Million USD | 2252.845% |
| Qrons Inc. | -643.67 Thousand USD | 7558.064% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 717.123% |
| CSL Limited | 3.7 Billion USD | 98.703% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 368.985% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 1051.65% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 7088.258% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 186.485% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 11654.336% |
| Rebus Holdings, Inc. | -664 Thousand USD | 7329.795% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 3694.783% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 12422.777% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 402.499% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 166.874% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -876.759% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 18442.022% |
| SQZ Biotechnologies Company | -75.82 Million USD | 163.311% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 1784.116% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 3225.281% |
| Mesoblast Limited | -84.14 Million USD | 157.05% |
| Marizyme, Inc. | -34.08 Million USD | 240.835% |
| Genus plc | 6.4 Million USD | -650.091% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -392.749% |
| Pharming Group N.V. | -4.87 Million USD | 1083.818% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 2516.63% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 5254.27% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 674.92% |
| ContraFect Corporation | -56.88 Million USD | 184.385% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 1153.979% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 3524.119% |
| IMV Inc. | -38.67 Million USD | 224.137% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 1845.135% |
| MultiCell Technologies, Inc. | -722.81 USD | 6641657.394% |
| ONE Bio Corp. | 13.68 Million USD | -250.88% |
| Accustem Sciences Inc. | -3.74 Million USD | 1381.379% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 181.38% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 10037.822% |
| Q BioMed Inc. | -3.44 Million USD | 1493.244% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -1256.097% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 1927.039% |
| Biomind Labs Inc. | -1 Million USD | 4854.923% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 187.327% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 1754.661% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 822.108% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 2674.91% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 160375.911% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 2583.99% |
| GB Sciences, Inc. | -1.42 Million USD | 3479.482% |
| Alpha Cognition Inc. | -9.7 Million USD | 594.62% |
| HST Global, Inc. | -140.9 Thousand USD | 34169.167% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 4367.542% |
| Halberd Corporation | -75.05 Thousand USD | 64065.145% |
| Enzolytics Inc. | -2.14 Million USD | 2334.077% |
| Agentix Corp. | -1.37 Million USD | 3599.59% |
| Resverlogix Corp. | -12.74 Million USD | 476.546% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 1615.205% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 111.294% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 4698.261% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 1744.349% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 3139.585% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 1509.872% |
| AVAX Technologies, Inc. | 6.69 Million USD | -617.267% |
| Zenith Capital Corp. | -8.94 Million USD | 636.798% |
| Genscript Biotech Corporation | -415.79 Million USD | 111.546% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 275663.062% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 2055.179% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 28090.187% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 2494.597% |
| Kadimastem Ltd | -3.04 Million USD | 1679.01% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 4978.38% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 26551.685% |
| LadRx Corporation | -3.82 Million USD | 1355.506% |
| Cell Source, Inc. | -4.32 Million USD | 1209.873% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 7088.258% |
| NovAccess Global Inc. | -2.46 Million USD | 2046.109% |
| Affymax, Inc. | -15.04 Million USD | 419.06% |
| Itoco Inc. | -919.14 Thousand USD | 5322.908% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 1232.637% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 4390.066% |
| Mobile Lads Corp. | -554.55 Thousand USD | 8756.72% |
| CytoDyn Inc. | -18.05 Million USD | 365.843% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 190826.424% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 21913.103% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 8600.777% |
| SYBLEU INC | -149.18 Thousand USD | 32279.81% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 2743.028% |
| International Stem Cell Corporation | -663 Thousand USD | 7340.7% |
| Bioxytran, Inc. | -3.82 Million USD | 1356.649% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 91296.506% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 236116.917% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 232.371% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 3066.986% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 6623.995% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 1643.1% |
| Neutra Corp. | -229.48 Thousand USD | 21018.854% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 373.709% |
| PureTech Health plc | -146.19 Million USD | 132.836% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 323.375% |
| IXICO plc | -1.43 Million USD | 3440.699% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 605.804% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 139.412% |
| CSL Limited | 3.81 Billion USD | 98.741% |
| Cellectis S.A. | -108.85 Million USD | 144.1% |